Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stereotactic Versus Conventional Radiotherapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer: A Bayesian Reanalysis of the LUSTRE Randomized Trial.

Clinical lung cancer·2026
Same author

Correction: Prospective study on <sup>18</sup>F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma.

British journal of cancer·2026
Same author

Prospective study on <sup>18</sup>F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma.

British journal of cancer·2026
Same author

Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial.

International journal of radiation oncology, biology, physics·2025
Same author

<sup>18</sup>F-FDG PET/CT of Oligometastatic Disease in Locally Advanced Breast Cancer: PETABC Trial Post Hoc Analysis.

Radiology·2025
Same author

The Association of Insomnia with Febrile Neutropenia, Leucopenia, and Infection in Women Receiving Adjuvant Chemotherapy for Breast Cancer.

Cancers·2025

Related Experiment Video

Updated: Jul 12, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Adjuvant therapy and thrombosis: how to avoid the problem?

Mark N Levine1

  • 1Department of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, Ont., Canada. mlevine@mcmaster.ca

Breast (Edinburgh, Scotland)
|August 28, 2007
PubMed
Summary
This summary is machine-generated.

Breast cancer patients face thrombosis risks, especially with chemotherapy and tamoxifen. Newer targeted therapies and oral anticoagulants may reduce these complications in the future.

Related Experiment Videos

Last Updated: Jul 12, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Thrombosis management in breast cancer is complicated by the need for anticoagulant therapy.
  • Venous thrombosis pathogenesis in breast cancer involves Virchow's triad: venous stasis, hypercoagulability, and vessel wall injury.
  • Chemotherapy and indwelling catheters contribute to vessel wall injury and hypercoagulability.

Purpose of the Study:

  • To review the occurrence and pathogenesis of venous thrombosis in breast cancer patients.
  • To analyze thrombotic rates associated with common breast cancer therapies, including tamoxifen, aromatase inhibitors, and chemotherapy.
  • To discuss strategies for reducing thrombosis and future directions in prevention.

Main Methods:

  • Literature review of studies on thrombosis in breast cancer patients.
  • Analysis of thrombotic rates for tamoxifen, aromatase inhibitors, and adjuvant chemotherapy.
  • Discussion of risk factors and potential preventative measures.

Main Results:

  • Tamoxifen is associated with a thrombosis rate of approximately 0.9%.
  • Aromatase inhibitors do not appear to increase venous thrombosis risk.
  • Thrombotic rates in early-stage breast cancer patients receiving adjuvant chemotherapy range from 3% to 8%, with higher rates in post-menopausal women and those on combination therapy.

Conclusions:

  • Thrombosis is a significant complication in breast cancer management, influenced by treatment modalities.
  • Avoiding unnecessary chemotherapy and utilizing novel targeted and antithrombotic agents are potential strategies for reducing thrombotic risk.
  • Future oral anticoagulants may offer safer and more convenient options for oncologists to prevent thrombosis.